Cognito Therapeutics closed a $105 million Series C round to advance its Spectris non‑invasive neurostimulation platform through a pivotal HOPE study in Alzheimer’s disease and to prepare for regulatory submission and commercialization. The round was led by Morningside Ventures, IAG Capital Partners, and Starbloom Capital. Cognito’s Spectris uses patterned visual and auditory stimulation designed to entrain neural network activity and restore coordinated brain rhythms; the company plans an at‑home, physician‑prescribed therapy if clinical data support efficacy. Cognito said funding will support the upcoming pivotal readout and scale‑up for commercial deployment. The financing highlights growing investor interest in nonpharmacologic neuromodulation approaches for neurodegeneration and the appetite for capital to bridge pivotal trials to potential market entry.